Global Sustained Release Ocular Drug Delivery Systems 麻豆原创 Growth 2025-2031

Publication ID:

LPI01256101

Publication Date:

January 16, 2025

Pages:

124

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Sustained Release Ocular Drug Delivery Systems market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The 鈥淪ustained Release Ocular Drug Delivery Systems Industry Forecast鈥� looks at past sales and reviews total world Sustained Release Ocular Drug Delivery Systems sales in 2024, providing a comprehensive analysis by region and market sector of projected Sustained Release Ocular Drug Delivery Systems sales for 2025 through 2031. With Sustained Release Ocular Drug Delivery Systems sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Sustained Release Ocular Drug Delivery Systems industry.
This Insight Report provides a comprehensive analysis of the global Sustained Release Ocular Drug Delivery Systems landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Sustained Release Ocular Drug Delivery Systems portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Sustained Release Ocular Drug Delivery Systems market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Sustained Release Ocular Drug Delivery Systems and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Sustained Release Ocular Drug Delivery Systems.
This report presents a comprehensive overview, market shares, and growth opportunities of Sustained Release Ocular Drug Delivery Systems market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Liposome
Microcapsules/Nanocapsules
Microspheres/Nanosptheres
Implants
Segmentation by Application:
Cataract
Glaucoma
Corneal Transplantation
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
pSivida
Allergan
Icon Bioscience
Ocular Therapeutix
Neurotech Pharmaceuticals
Santen Pharmaceutical
Aciont Inc.
Envisia Therapeutics
GrayBug
Innocore Pharmaceuticals
OHR Pharmaceuticals
PolyActiva
TheraKine
Key Questions Addressed in this Report
What is the 10-year outlook for the global Sustained Release Ocular Drug Delivery Systems market?
What factors are driving Sustained Release Ocular Drug Delivery Systems market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Sustained Release Ocular Drug Delivery Systems market opportunities vary by end market size?
How does Sustained Release Ocular Drug Delivery Systems break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Sustained Release Ocular Drug Delivery Systems Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Sustained Release Ocular Drug Delivery Systems by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Sustained Release Ocular Drug Delivery Systems by Country/Region, 2020, 2024 & 2031
2.2 Sustained Release Ocular Drug Delivery Systems Segment by Type
2.2.1 Liposome
2.2.2 Microcapsules/Nanocapsules
2.2.3 Microspheres/Nanosptheres
2.2.4 Implants
2.3 Sustained Release Ocular Drug Delivery Systems Sales by Type
2.3.1 Global Sustained Release Ocular Drug Delivery Systems Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Sustained Release Ocular Drug Delivery Systems Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Sustained Release Ocular Drug Delivery Systems Sale Price by Type (2020-2025)
2.4 Sustained Release Ocular Drug Delivery Systems Segment by Application
2.4.1 Cataract
2.4.2 Glaucoma
2.4.3 Corneal Transplantation
2.4.4 Others
2.5 Sustained Release Ocular Drug Delivery Systems Sales by Application
2.5.1 Global Sustained Release Ocular Drug Delivery Systems Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Sustained Release Ocular Drug Delivery Systems Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Sustained Release Ocular Drug Delivery Systems Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Sustained Release Ocular Drug Delivery Systems Breakdown Data by Company
3.1.1 Global Sustained Release Ocular Drug Delivery Systems Annual Sales by Company (2020-2025)
3.1.2 Global Sustained Release Ocular Drug Delivery Systems Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Sustained Release Ocular Drug Delivery Systems Annual Revenue by Company (2020-2025)
3.2.1 Global Sustained Release Ocular Drug Delivery Systems Revenue by Company (2020-2025)
3.2.2 Global Sustained Release Ocular Drug Delivery Systems Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Sustained Release Ocular Drug Delivery Systems Sale Price by Company
3.4 Key Manufacturers Sustained Release Ocular Drug Delivery Systems Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Sustained Release Ocular Drug Delivery Systems Product Location Distribution
3.4.2 Players Sustained Release Ocular Drug Delivery Systems Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Sustained Release Ocular Drug Delivery Systems by Geographic Region
4.1 World Historic Sustained Release Ocular Drug Delivery Systems 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Sustained Release Ocular Drug Delivery Systems Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Sustained Release Ocular Drug Delivery Systems Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Sustained Release Ocular Drug Delivery Systems 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Sustained Release Ocular Drug Delivery Systems Annual Sales by Country/Region (2020-2025)
4.2.2 Global Sustained Release Ocular Drug Delivery Systems Annual Revenue by Country/Region (2020-2025)
4.3 Americas Sustained Release Ocular Drug Delivery Systems Sales Growth
4.4 APAC Sustained Release Ocular Drug Delivery Systems Sales Growth
4.5 Europe Sustained Release Ocular Drug Delivery Systems Sales Growth
4.6 Middle East & Africa Sustained Release Ocular Drug Delivery Systems Sales Growth
5 Americas
5.1 Americas Sustained Release Ocular Drug Delivery Systems Sales by Country
5.1.1 Americas Sustained Release Ocular Drug Delivery Systems Sales by Country (2020-2025)
5.1.2 Americas Sustained Release Ocular Drug Delivery Systems Revenue by Country (2020-2025)
5.2 Americas Sustained Release Ocular Drug Delivery Systems Sales by Type (2020-2025)
5.3 Americas Sustained Release Ocular Drug Delivery Systems Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Sustained Release Ocular Drug Delivery Systems Sales by Region
6.1.1 APAC Sustained Release Ocular Drug Delivery Systems Sales by Region (2020-2025)
6.1.2 APAC Sustained Release Ocular Drug Delivery Systems Revenue by Region (2020-2025)
6.2 APAC Sustained Release Ocular Drug Delivery Systems Sales by Type (2020-2025)
6.3 APAC Sustained Release Ocular Drug Delivery Systems Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Sustained Release Ocular Drug Delivery Systems by Country
7.1.1 Europe Sustained Release Ocular Drug Delivery Systems Sales by Country (2020-2025)
7.1.2 Europe Sustained Release Ocular Drug Delivery Systems Revenue by Country (2020-2025)
7.2 Europe Sustained Release Ocular Drug Delivery Systems Sales by Type (2020-2025)
7.3 Europe Sustained Release Ocular Drug Delivery Systems Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Sustained Release Ocular Drug Delivery Systems by Country
8.1.1 Middle East & Africa Sustained Release Ocular Drug Delivery Systems Sales by Country (2020-2025)
8.1.2 Middle East & Africa Sustained Release Ocular Drug Delivery Systems Revenue by Country (2020-2025)
8.2 Middle East & Africa Sustained Release Ocular Drug Delivery Systems Sales by Type (2020-2025)
8.3 Middle East & Africa Sustained Release Ocular Drug Delivery Systems Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Sustained Release Ocular Drug Delivery Systems
10.3 Manufacturing Process Analysis of Sustained Release Ocular Drug Delivery Systems
10.4 Industry Chain Structure of Sustained Release Ocular Drug Delivery Systems
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Sustained Release Ocular Drug Delivery Systems Distributors
11.3 Sustained Release Ocular Drug Delivery Systems Customer
12 World Forecast Review for Sustained Release Ocular Drug Delivery Systems by Geographic Region
12.1 Global Sustained Release Ocular Drug Delivery Systems 麻豆原创 Size Forecast by Region
12.1.1 Global Sustained Release Ocular Drug Delivery Systems Forecast by Region (2026-2031)
12.1.2 Global Sustained Release Ocular Drug Delivery Systems Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Sustained Release Ocular Drug Delivery Systems Forecast by Type (2026-2031)
12.7 Global Sustained Release Ocular Drug Delivery Systems Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 pSivida
13.1.1 pSivida Company Information
13.1.2 pSivida Sustained Release Ocular Drug Delivery Systems Product Portfolios and Specifications
13.1.3 pSivida Sustained Release Ocular Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 pSivida Main Business Overview
13.1.5 pSivida Latest Developments
13.2 Allergan
13.2.1 Allergan Company Information
13.2.2 Allergan Sustained Release Ocular Drug Delivery Systems Product Portfolios and Specifications
13.2.3 Allergan Sustained Release Ocular Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Allergan Main Business Overview
13.2.5 Allergan Latest Developments
13.3 Icon Bioscience
13.3.1 Icon Bioscience Company Information
13.3.2 Icon Bioscience Sustained Release Ocular Drug Delivery Systems Product Portfolios and Specifications
13.3.3 Icon Bioscience Sustained Release Ocular Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Icon Bioscience Main Business Overview
13.3.5 Icon Bioscience Latest Developments
13.4 Ocular Therapeutix
13.4.1 Ocular Therapeutix Company Information
13.4.2 Ocular Therapeutix Sustained Release Ocular Drug Delivery Systems Product Portfolios and Specifications
13.4.3 Ocular Therapeutix Sustained Release Ocular Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Ocular Therapeutix Main Business Overview
13.4.5 Ocular Therapeutix Latest Developments
13.5 Neurotech Pharmaceuticals
13.5.1 Neurotech Pharmaceuticals Company Information
13.5.2 Neurotech Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Product Portfolios and Specifications
13.5.3 Neurotech Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Neurotech Pharmaceuticals Main Business Overview
13.5.5 Neurotech Pharmaceuticals Latest Developments
13.6 Santen Pharmaceutical
13.6.1 Santen Pharmaceutical Company Information
13.6.2 Santen Pharmaceutical Sustained Release Ocular Drug Delivery Systems Product Portfolios and Specifications
13.6.3 Santen Pharmaceutical Sustained Release Ocular Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Santen Pharmaceutical Main Business Overview
13.6.5 Santen Pharmaceutical Latest Developments
13.7 Aciont Inc.
13.7.1 Aciont Inc. Company Information
13.7.2 Aciont Inc. Sustained Release Ocular Drug Delivery Systems Product Portfolios and Specifications
13.7.3 Aciont Inc. Sustained Release Ocular Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Aciont Inc. Main Business Overview
13.7.5 Aciont Inc. Latest Developments
13.8 Envisia Therapeutics
13.8.1 Envisia Therapeutics Company Information
13.8.2 Envisia Therapeutics Sustained Release Ocular Drug Delivery Systems Product Portfolios and Specifications
13.8.3 Envisia Therapeutics Sustained Release Ocular Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Envisia Therapeutics Main Business Overview
13.8.5 Envisia Therapeutics Latest Developments
13.9 GrayBug
13.9.1 GrayBug Company Information
13.9.2 GrayBug Sustained Release Ocular Drug Delivery Systems Product Portfolios and Specifications
13.9.3 GrayBug Sustained Release Ocular Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 GrayBug Main Business Overview
13.9.5 GrayBug Latest Developments
13.10 Innocore Pharmaceuticals
13.10.1 Innocore Pharmaceuticals Company Information
13.10.2 Innocore Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Product Portfolios and Specifications
13.10.3 Innocore Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Innocore Pharmaceuticals Main Business Overview
13.10.5 Innocore Pharmaceuticals Latest Developments
13.11 OHR Pharmaceuticals
13.11.1 OHR Pharmaceuticals Company Information
13.11.2 OHR Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Product Portfolios and Specifications
13.11.3 OHR Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 OHR Pharmaceuticals Main Business Overview
13.11.5 OHR Pharmaceuticals Latest Developments
13.12 PolyActiva
13.12.1 PolyActiva Company Information
13.12.2 PolyActiva Sustained Release Ocular Drug Delivery Systems Product Portfolios and Specifications
13.12.3 PolyActiva Sustained Release Ocular Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 PolyActiva Main Business Overview
13.12.5 PolyActiva Latest Developments
13.13 TheraKine
13.13.1 TheraKine Company Information
13.13.2 TheraKine Sustained Release Ocular Drug Delivery Systems Product Portfolios and Specifications
13.13.3 TheraKine Sustained Release Ocular Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 TheraKine Main Business Overview
13.13.5 TheraKine Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.